Recommendations

116
Smith et al. 2005
ACC/AHA/SCAI Practice Guidelines
ACC - www.acc.org
AHA - www.americanheart.org
SCAI - www.scai.org
REPLACE-2 trial. Semin Thromb Hemost 2004;30:329-36.
746. Angiomax (bivalirudin) for injection. Package Insert. The
Medicine Company, Parsippany, NJ. Available at http://www.
themedicinescompany.com/~products_content/PN16019gt2.pdf.
Accessed May 27, 2005.
747. Argatroban Injection. Prescribing Information. GlaxoSmithKline,
Research Triangle, NC. Available at: http://us.gsk.com/products/assets/us_argatroban.pdf.
Accessed May 27, 2005.
748. Mandak JS, Blankenship JC, Gardner LH, et al. Modifiable risk
factors for vascular access site complications in the IMPACT II
Trial of angioplasty with versus without eptifibatide. Integrilin to
Minimize Platelet Aggregation and Coronary Thrombosis. J Am
Coll Cardiol 1998;31:1518-24.
749. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications
with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin
in patients undergoing percutaneous coronary intervention.
EPIC Investigators. Circulation 1995;91:2882-90.
750. Blankenship JC, Hellkamp AS, Aguirre FV, Demko SL, Topol EJ,
Califf RM. Vascular access site complications after percutaneous
coronary intervention with abciximab in the Evaluation of c7E3
for the Prevention of Ischemic Complications (EPIC) trial. Am J
Cardiol 1998;81:36-40.
751. Kereiakes DJ, Montalescot G, Antman EM, et al. Low-molecularweight
heparin therapy for non-ST-elevation acute coronary syndromes
and during percutaneous coronary intervention: an expert
consensus. Am Heart J 2002;144:615-24.
752. Fox KA, Antman EM, Cohen M, Bigonzi F. Comparison of
enoxaparin versus unfractionated heparin in patients with unstable
angina pectoris/non-ST-segment elevation acute myocardial
infarction having subsequent percutaneous coronary intervention.
Am J Cardiol 2002;90:477-82.
753. Koreny M, Riedmuller E, Nikfardjam M, Siostrzonek P, Mullner
M. Arterial puncture closing devices compared with standard
manual compression after cardiac catheterization: systematic
review and meta-analysis. JAMA 2004;291:350-7.
754. Laarman GJ, Kiemeneij F, van der Wieken LR, Tijssen JG,
Suwarganda JS, Slagboom T. A pilot study of coronary angioplasty
in outpatients. Br Heart J 1994;72:12-5.
755. Cragg DR, Friedman HA, Almany SL, et al. Early hospital discharge
after percutaneous transluminal coronary angioplasty. Am
J Cardiol 1989;64:1270-4.
756. Mann T, Cowper PA, Peterson ED, et al. Transradial coronary
stenting: comparison with femoral access closed with an arterial
suture device. Catheter Cardiovasc Interv 2000;49:150-6.
757. Johnson LW, Esente P, Giambartolomei A, et al. Peripheral vascular
complications of coronary angioplasty by the femoral and
brachial techniques. Cathet Cardiovasc Diagn 1994;31:165-72.
758. Skillman JJ, Kim D, Baim DS. Vascular complications of percutaneous
femoral cardiac interventions: incidence and operative
repair. Arch Surg 1988;123:1207-12.
759. Khoury M, Batra S, Berg R, Rama K, Kozul V. Influence of arterial
access sites and interventional procedures on vascular complications
after cardiac catheterizations. Am J Surg 1992;164:205-9.
760. Kresowik TF, Khoury MD, Miller BV, et al. A prospective study
of the incidence and natural history of femoral vascular complications
after percutaneous transluminal coronary angioplasty. J
Vasc Surg 1991;13:328-33; discussion 333-5.
761. Lumsden AB, Miller JM, Kosinski AS, et al. A prospective evaluation
of surgically treated groin complications following percutaneous
cardiac procedures. Am Surg 1994;60:132-7.
762. Muller DW, Shamir KJ, Ellis SG, Topol EJ. Peripheral vascular
complications after conventional and complex percutaneous coro-
nary interventional procedures. Am J Cardiol 1992;69:63-8.
763. Agrawal SK, Pinheiro L, Roubin GS, et al. Nonsurgical closure of
femoral pseudoaneurysms complicating cardiac catheterization
and percutaneous transluminal coronary angioplasty. J Am Coll
Cardiol 1992;20:610-5.
764. Bogart DB, Bogart MA, Miller JT, Farrar MW, Barr WK,
Montgomery MA. Femoral artery catheterization complications: a
study of 503 consecutive patients. Cathet Cardiovasc Diagn 1995;
34:8-13.
765. Kent KC, Moscucci M, Mansour KA, et al. Retroperitoneal
hematoma after cardiac catheterization: prevalence, risk factors,
and optimal management. J Vasc Surg 1994;20:905-10; discussion
910-3.
766. Feld R, Patton GM, Carabasi RA, Alexander A, Merton D,
Needleman L. Treatment of iatrogenic femoral artery injuries with
ultrasound-guided compression. J Vasc Surg 1992;16:832-40.
767. Schaub F, Theiss W, Heinz M, Zagel M, Schomig A. New aspects
in ultrasound-guided compression repair of postcatheterization
femoral artery injuries. Circulation 1994;90:1861-5.
768. Kim D, Orron DE, Skillman JJ, et al. Role of superficial femoral
artery puncture in the development of pseudoaneurysm and arteriovenous
fistula complicating percutaneous transfemoral cardiac
catheterization. Cathet Cardiovasc Diagn 1992;25:91-7.
769. Nikolsky E, Mehran R, Halkin A, et al. Vascular complications
associated with arteriotomy closure devices in patients undergoing
percutaneous coronary procedures: a meta-analysis. J Am Coll
Cardiol 2004;44:1200-9.
770. Sanborn TA, Gibbs HH, Brinker JA, Knopf WD, Kosinski EJ,
Roubin GS. A multicenter randomized trial comparing a percutaneous
collagen hemostasis device with conventional manual compression
after diagnostic angiography and angioplasty. J Am Coll
Cardiol 1993;22:1273-9.
771. Silber S. Hemostasis success rates and local complications with
collagen after femoral access for cardiac catheterization: analysis
of 6007 published patients. Am Heart J 1998;135:152-6.
772. Kussmaul WG, Buchbinder M, Whitlow PL, et al. Femoral artery
hemostasis using an implantable device (Angio-Seal) after coronary
angioplasty. Cathet Cardiovasc Diagn 1996;37:362-5.
773. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for
prediction of contrast-induced nephropathy after percutaneous
coronary intervention: development and initial validation. J Am
Coll Cardiol 2004;44:1393-9.
774. Maeder M, Klein M, Fehr T, Rickli H. Contrast nephropathy: review
focusing on prevention. J Am Coll Cardiol 2004;44:1763-71.
775. Levine GN, Kern MJ, Berger PB, et al. Management of patients
undergoing percutaneous coronary revascularization. Ann Intern
Med 2003;139:123-36.
776. Aguilar C, Reza A, Garcia JE, Rull JA. Biguanide related lactic
acidosis: incidence and risk factors. Arch Med Res 1992;23:19-24.
777. Agrawal M, Stouffer GA. Cardiology Grand Rounds from The
University of North Carolina at Chapel Hill. Contrast induced
nephropathy after angiography. Am J Med Sci 2002;323:252-8.
778. Kuntz RE, Piana R, Pomerantz RM, et al. Changing incidence and
management of abrupt closure following coronary intervention in
the new device era. Cathet Cardiovasc Diagn 1992;27:183-90.
779. Simpfendorfer C, Belardi J, Bellamy G, Galan K, Franco I,
Hollman J. Frequency, management and follow-up of patients
with acute coronary occlusions after percutaneous transluminal
coronary angioplasty. Am J Cardiol 1987;59:267-9.
780. de Feyter PJ, de Jaegrere PP, Serruys PW. Incidence, predictors,
and management of acute coronary occlusion after coronary
angioplasty. Am Heart J 1994;127:643-51.